

Cite this: *RSC Adv.*, 2018, 8, 22062

A galactose-mediated targeting nanoprobe for intracellular hydroxyl radical imaging to predict drug-induced liver injury†

Bailing Ma, Mi Lu, Bo-Yang Yu * and Jiangwei Tian *

Drug-induced liver injury (DILI) is a serious concern in modern medicine due to its unpredictability. Currently, biochemical serum markers are being used in DILI detection. However, these biomarker-based methods lack sensitivity and specificity. A high intracellular level of hydroxyl radicals ($\cdot\text{OH}$) has been regarded as an early indicator of DILI. Therefore, we proposed an $\cdot\text{OH}$ -responsive and hepatocyte-targeted nanoprobe *via* conjugation of carboxyfluorescein-labeled DNA and pegylated galactose on the surface of gold nanoparticles. The nanoprobe could bind to a hepatocyte-specific asialoglycoprotein receptor through galactose, and it could be internalized into liver cells. In the presence of high levels of $\cdot\text{OH}$ in DILI, the DNA could be cleaved to release carboxyfluorescein, leading to remarkable fluorescence enhancement for $\cdot\text{OH}$ detection. Confocal fluorescence imaging demonstrated that the nanoprobe could be successfully applied in monitoring high $\cdot\text{OH}$ levels resulting from acetaminophen or triptolide-induced liver injury, which may provide a simple but powerful protocol for the prediction of DILI.

Received 14th February 2018

Accepted 4th June 2018

DOI: 10.1039/c8ra01424h

rsc.li/rsc-advances

Introduction

Drug-induced liver injury (DILI) is a long-standing concern and a serious problem in modern medicine.^{1–3} The liver is extremely vulnerable to various drugs and/or their metabolites because the majority of detoxification occurs in the liver.^{4,5} DILI has become an important problem in drug development and has caused the withdrawal of the approved drugs from the market in the pharmaceutical industry.^{6–8} Furthermore, the incidence of DILI has increased significantly due to the abuse of drugs.⁹ Hence, the early detection of potential drug-induced hepatotoxicity during the drug exploitation process and preclinical development is of paramount importance.

Serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) are commonly used as the gold standard indicators for evaluating liver injury in clinical practice.^{10,11} However, these clinical biomarkers used for DILI detection are generally nonspecific and hysteric in detecting liver damage. Thus, the development of a more selective and sensitive method is highly desired for the detection of drug-induced hepatotoxicity. Recently, reactive oxygen species (ROS) have been reported as distinct sources of production by


direct or indirect oxidation of phase I metabolizing enzymes in the early DILI process.^{12–16} In particular, the hydroxyl radical ($\cdot\text{OH}$) is the strongest oxidizing agent among ROS, and it can cause irreversible oxidative damage to DNA.^{17–20} Therefore, the accurate detection of endogenous $\cdot\text{OH}$ during DILI may contribute insights into the mechanism of drug-induced hepatotoxicity.

To achieve this goal, an $\cdot\text{OH}$ -responsive and hepatocyte-targeted nanoprobe based on Förster resonance energy transfer (FRET) was developed in this work to evaluate the drug-induced hepatotoxicity. The nanoprobe was constructed by covalent conjugation of thiolated single-stranded oligonucleotide labelled with carboxyfluorescein (HS-AGGGTTAGGG-FAM) and thiol-poly(ethylene glycol)2000-galactose (HS-PEG₂₀₀₀-Gal) on the surface of gold nanoparticles (AuNPs). Due to the high quenching efficiency,²¹ convenient surface modification²² and good biocompatibility²³ of AuNPs, they can serve as ideal carriers and electron acceptors in the prepared nanoprobe. The close proximity of AGGGTTAGGG-FAM to AuNP results in strong inhibition of FAM fluorescence due to the FRET effect. Additionally, PEG₂₀₀₀-Gal is also immobilized on the surface of AuNPs to ensure stability and specific recognition toward the asialoglycoprotein receptor (ASGPR)-rich hepatocyte.^{24,25} After the nanoprobe is specifically internalized into the liver cells through ASGPR-mediated endocytosis, AGGGTTAGGG with TT as the recognition sequence²⁶ can be cleaved by $\cdot\text{OH}$ during DILI to release FAM from the surface of AuNPs, leading to a distinct fluorescence enhancement at 520 nm. By virtue of confocal fluorescence imaging, DILI can be detected and visualized in a noninvasive manner in living cells,

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China. E-mail: boyangyu59@163.com; jw.tian@cpu.edu.cn

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra01424h





Scheme 1 A schematic illustration of (A) the structure of the nanoprobe and (B) function of fluorescence activation *via* elevated $\cdot\text{OH}$ levels during DILI in liver cells.

which provides a new method to detect DILI at an early stage (Scheme 1).

Results and discussion

Characterization of the nanoprobe

AuNPs were synthesized using the classical citrate reduction method.²⁷ The UV-Vis absorption spectrum of AuNPs revealed that the maximum absorption of AuNPs was at 519 nm (Fig. S1†). In addition, the absorption spectrum of AuNPs overlapped with the emission spectrum of FAM, which peaked at 520 nm, and this indicated that the fluorescence of FAM could be effectively quenched by AuNPs due to the FRET effect.

The transmission electron microscopy (TEM) image verified the formation of uniform and spherical AuNPs (Fig. 1A), and the average hydrodynamic diameter of AuNPs was measured to be approximately 15.6 nm by dynamic light scattering (DLS) (Fig. 1A). The nanoprobe was synthesized through a rapid and facile method based on the synergistic protection effect of PEG on AuNPs.²⁸ The TEM image (Fig. 1B) exhibited that the nanoprobe was similar to AuNPs but with high dispersibility owing to successful PEG conjugation. Meanwhile, the DLS result showed that the hydrodynamic diameter of the nanoprobe increased from approximately 15.6 nm (Fig. 1A) to 22.0 nm (Fig. 1B), indicating that the surface coating of PEG₂₀₀₀-Gal and oligonucleotides increased the size of the nanoprobe. Furthermore, the zeta potential of AuNPs was measured to be -34.2 mV (Fig. 1C), which suggested high stability of AuNPs due to the presence of the negatively charged citrate ligand. The zeta potential of the nanoprobe increased to -14.9 mV; this could be because the citrate salt on the surface of AuNPs was replaced by PEG₂₀₀₀-Gal and oligonucleotides *via* a ligand exchange reaction. The zeta potential was approximately -15 mV, indicating that the nanoprobe was still stable in aqueous solution.²⁹ Moreover, in contrast to the UV-Vis spectrum of AuNPs with only one absorption peak at 519 nm, the UV-Vis spectrum of the nanoprobe exhibited an extra characteristic DNA peak at 260 nm (Fig. 1D), confirming the successful conjugation of DNA sequences on the AuNP surface. The number of DNA molecules modified on the AuNPs was calculated based on the mercaptoethanol reduction method.³⁰ It was confirmed that each AuNP carried approximately 159 ± 2 FAM-DNA (Fig. S2†). Taken together, these results indicated that the nanoprobe was successfully assembled.

Response of the nanoprobe toward $\cdot\text{OH}$

After characterization of the nanoprobe, we tested its fluorescence response toward $\cdot\text{OH}$ generated by a Fenton reaction ($\text{Fe}^{2+} + \text{H}_2\text{O}_2 = \text{Fe}^{3+} + \text{OH}^- + \cdot\text{OH}$) using different concentrations of Fe^{2+} and excessive H_2O_2 (1 : 6 mol per mol).³¹ Therefore, the concentration of Fe^{2+} in the Fenton reaction served as the concentration of $\cdot\text{OH}$ in the following experiments. There was almost no background fluorescence in the absence of $\cdot\text{OH}$ (Fig. 2A and B) because of the high quenching efficiency of AuNPs with respect to FAM. After the addition of $1 \mu\text{M}$ $\cdot\text{OH}$, a significant fluorescence enhancement of the nanoprobe was observed owing to the elimination of the FRET effect, which was induced by the cleavage of DNA. Kinetic studies showed that the nanoprobe responded to $\cdot\text{OH}$ within 15 min (Fig. S3†). The relatively long response time could be ascribed to the slow Fenton reaction with a rate constant of $40\text{--}80 \text{ mol}^{-1} \text{ L s}^{-1}$.³² Furthermore, when dimethyl sulfoxide (DMSO) as a typical $\cdot\text{OH}$ scavenger³³ was added into the reaction mixture of Fe^{2+} and H_2O_2 , the fluorescence of the nanoprobe was significantly suppressed, confirming that the emission of the nanoprobe was due to the $\cdot\text{OH}$ -induced breakage of DNA chains. The fluorescence intensity of the nanoprobe increased gradually along with the concentration of $\cdot\text{OH}$ from 0 to $1 \mu\text{M}$ (Fig. 2C). A good linear correlation between the fluorescence intensity and




Fig. 1 (A) TEM image (inset) and size distribution of AuNPs. (B) TEM image (inset) and size distribution of the nanoprobe. (C) Zeta potentials of AuNPs and the nanoprobe. (D) Absorption spectra of AuNPs and the nanoprobe.






Fig. 2 (A) Fluorescence spectral responses and (B) relative fluorescence intensity (F/F_0) at 520 nm of the nanoprobe with respect to $\cdot\text{OH}$ in the absence or presence of DMSO. (C) Fluorescence spectra of 1 nM nanoprobe after addition of 0, 0.01, 0.1, 0.2, 0.4, 0.6, 0.8 and 1 μM $\cdot\text{OH}$. (D) Linear correlation between $\cdot\text{OH}$ concentration and fluorescence intensity at 520 nm. Data are means \pm SD ($n = 3$).

concentration of $\cdot\text{OH}$ was obtained with $F = 6.52179 + 71.76379 [\cdot\text{OH}]$ ($R^2 = 0.9963$) (Fig. 2D). The selectivity of the nanoprobe towards $\cdot\text{OH}$ was examined by monitoring the fluorescence changes in the presence of various ROS, reactive nitrogen species (RNS) and iron. Significant fluorescence enhancement was observed for $\cdot\text{OH}$, whereas other interferences could not induce the fluorescence change, verifying the high selectivity of the nanoprobe towards $\cdot\text{OH}$ (Fig. S4†). The fluorescent stability of the nanoprobe was also investigated in phosphate buffered saline (PBS) and Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). The fluorescence of the nanoprobe showed negligible changes in these two media from 1 to 7 days (Fig. S5†). The results revealed the sensitivity, specificity and stability of the nanoprobe for $\cdot\text{OH}$ detection.

Biocompatibility of the nanoprobe

To evaluate the biocompatibility of the nanoprobe in living cells, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was carried out in the human normal liver cell line L-02. The absorbance of the produced formazan at 490 nm depends on the cell viability. The MTT assay showed that AuNPs and the nanoprobe were almost noncytotoxic to living cells at concentrations of up to 2.5 nM (Fig. 3A) after 24 h incubation (Fig. 3B), which revealed that the nanoprobe exhibited good biocompatibility in living cells.

Cellular uptake of the nanoprobe

After incubation with liver cells, it was found that the intracellular amount of the nanoprobe was much more than that of the nanoprobe without Gal (Fig. 4). The galactose residue of PEG₂₀₀₀-Gal exposed on the surface of the nanoprobe could promote cellular uptake of the nanoprobe into hepatocytes by




Fig. 3 (A) MTT assay of L-02 cells incubated with varying concentrations of AuNPs and the nanoprobe for 24 h. (B) MTT assay of L-02 cells treated with 1 nM AuNPs and the nanoprobe at different times. Data are means \pm SD ($n = 3$).

an ASGPR-mediated endocytosis pathway. The increased size of 100 nm of the intracellular nanoprobe was due to the trapping and aggregation of multiple nanoprobe in the lysosomal compartments. The result demonstrated that the nanoprobe with Gal modification could effectively target the liver cells.

Imaging of $\cdot\text{OH}$ in APAP-induced liver injury and the remediation effect of NAC or QUE

The nanoprobe was used to investigate the fluctuation in $\cdot\text{OH}$ levels in liver cells under different pathological conditions by confocal fluorescence imaging. Acetaminophen (APAP), a widely used analgesic and antipyretic drug, is mainly employed to treat pain and fever.³⁴ An overdose of APAP can result in the excessive production of ROS and RNS, which is a major cause of liver injury through enzymatic biotransformation^{35,36} The cell viability of L-02 cells decreased to 85% with a concentration of APAP of 8 mM (Fig. S6A†), and the intracellular ROS level clearly increased (Fig. S6B†), revealing that the cells were slightly injured by ROS. The L-02 cells were treated with APAP and




Fig. 4 TEM images of cellular uptake of nanoprobe (without Gal) and nanoprobe. The pictures displayed below are the enlarged views of the red frames.



incubated with the nanoprobe to perform confocal fluorescence imaging. The intracellular fluorescence intensity increased gradually with the increasing concentration of APAP (Fig. 5) and incubation time of the nanoprobe (Fig. S7†), which indicated $\cdot\text{OH}$ production in the process of APAP-induced liver cell injury. Conversely, no difference in the activity of ALT or AST as the classical serum biomarker was observed after the cells were treated with different concentrations of APAP for 4 h (†), which confirmed that $\cdot\text{OH}$ imaging using the nanoprobe was more sensitive than the conventional methods for DILI detection.

Subsequently, the nanoprobe was used to examine the protective effect of drugs on APAP-induced liver cell injury. *N*-acetylcysteine (NAC) and quercetin (QUE) as active ingredients for protecting against liver injury^{37–39} were added before the APAP treatment. NAC acts as an antidote to APAP-induced liver injury through upregulation of the intracellular GSH and elimination of ROS.^{37,38} QUE is an effective antioxidant, which can directly remove various free radicals and inhibit oxidative stress.³⁹ The MTT assay showed that NAC (Fig. S8A†) and QUE (Fig. S9A†) were nontoxic to L-02 cells. The 8 mM APAP-induced intracellular ROS production could be significantly suppressed by 2 mM NAC (Fig. S8B†) and 20 μM QUE (Fig. S9B†). Confocal fluorescence imaging revealed that pre-treatments with NAC (Fig. S10†) and QUE (Fig. S11†) could remarkably reduce the fluorescence of the nanoprobe compared to that of single APAP administration. These results verified that the nanoprobe can be employed to visualize the protective effects of NAC and QUE on APAP-induced liver cell injury.

Imaging of $\cdot\text{OH}$ in TP-induced liver injury

Triptolide (TP) is a diterpenoid triepoxide with a variety of biological activities.⁴⁰ However, the potential hepatotoxicity of TP is associated with the intracellular accumulation of ROS, which limits its clinical application.⁴¹ To investigate the hepatotoxicity of TP, L-02 cells were incubated with TP for performing MTT and ROS assays. There was only slight reduction in the cell viability of L-02 cells at a concentration of up to 120 nM (Fig. S12A†) and an incubation time of 12 h (Fig. S13A†). On the contrary, the level of intracellular ROS clearly increased at a concentration of 120 nM of TP (Fig. S12B†) and an incubation time of 12 h (Fig. S13B†), suggesting that the intracellular high-expression of ROS could be used as a more sensitive indicator to reflect the TP-induced liver cell injury. Therefore, the L-02 cells were treated with TP and then incubated with the nanoprobe to implement confocal fluorescence imaging. The




Fig. 6 (A) Confocal fluorescence, BF and merged images of L-02 cells treated with various concentrations of TP for 12 h and then incubated with 1 nM nanoprobe for 2 h. (B) Confocal fluorescence, BF and merged images of L-02 cells treated with 120 nM TP at different times and then incubated with 1 nM nanoprobe for 2 h. Scale bar: 20 μm .

green fluorescence of the nanoprobe in the L-02 cells increased gradually along with the increasing concentration (Fig. 6A) and time (Fig. 6B), and the fluorescence was distinct when the TP concentration was 60 nM and the incubation time was 6 h, indicating that the intracellular $\cdot\text{OH}$ generation during TP treatment could be detected by the nanoprobe at a low dosage and early time. We also determined the activity changes of ALT and AST in L-02 cells treated with various concentrations of TP for 12 h. No significant difference was found in the activities of ALT (Fig. S12C†) and AST (Fig. S12D†). L-02 cells were incubated with 120 nM TP for different times. After 24 h of TP administration, a remarkable change in the activities of ALT (Fig. S13C†) and AST (Fig. S13D†) could be observed. It is noteworthy that the positive time of 6 h using nanoprobe imaging was superior to that of 24 h for ALT- and AST-based conventional detection methods, demonstrating the generality and advantage of the nanoprobe for the early detection of DILI.

Experimental section

Materials and reagents

Chloroauric acid ($\text{HAuCl}_4 \cdot 4\text{H}_2\text{O}$, 99.99%), sodium citrate ($\text{Na}_3\text{C}_6\text{H}_5\text{O}_7$), sodium chloride (NaCl), tween20, hydrogen peroxide (H_2O_2 , 30%), sodium hypochlorite solution and ferrous sulfate ($\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$) were purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Acetaminophen (APAP), *N*-acetylcysteine (NAC) and triptolide (TP) were purchased from Aladdin Co. Ltd. (Shanghai, China).




Fig. 5 Confocal fluorescence, bright field (BF) and merged images of L-02 cells pre-treated with various concentrations of APAP for 4 h and then incubated with 1 nM nanoprobe for 2 h. Scale bar: 20 μm .



Ethylenediaminetetraacetic acid (EDTA), quercetin (QUE) and 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from KeyGen Biotech. Co. Ltd. (Nanjing, China). Quantitative detection kits for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). FAM-modified single-stranded oligonucleotide (5'-FAM-(CH₂)₆-AGGGTTAGGG-(CH₂)₃-SH-3') was synthesized and purified by Sangon Biotech Co. Ltd. (Shanghai, China). Thiol-poly(ethylene glycol)2000-galactose (HS-PEG₂₀₀₀-Gal) and thiol-monomethoxypolyethylene glycol 2000 (mPEG₂₀₀₀-SH) were synthesized and purified by Hunan Huateng Pharmaceutical Co. Ltd. (Hunan, China). All chemicals were of analytical grade and used without further purification. Ultrapure water was prepared using the Millipore Simplicity System (Millipore, Bedford, USA) with a resistivity of 18.2 MΩ.

Apparatus

Absorption spectra were recorded on an UV-2550 UV-Vis spectrophotometer (Shimadzu Company, Japan). Fluorescence spectra were measured on a Carry Eclipse Fluorescence spectrophotometer (Agilent, USA). The hydrodynamic diameters of the nanoparticles were measured by dynamic light scattering (DLS) at 25 °C using 90 Plus/BI-MAS equipment (Brookhaven, USA). The morphology of the nanoparticle was characterized with a Hitachi HT7700 transmission electron microscope (TEM) operating at 200 kV. Zeta potential measurements were obtained at 25 °C on a Zetasizer (Nano-Z, Malvern, UK). The MTT assay was measured by a microplate reader (Biotek, USA). Confocal fluorescence imaging of cells was performed on a confocal laser scanning microscope (CLSM, LSM800, Zeiss, Germany).

Preparation of AuNPs and the nanoprobe

AuNPs were prepared by the citrate reduction method.⁴² In brief, 10 mL trisodium citrate (0.25%) was rapidly added into a boiling 100 mL HAuCl₄ solution (0.01%) with strong stirring. The solution was maintained with continuous stirring for 30 min. Afterwards, the solution was allowed to cool to room temperature and stored at 4 °C. The AuNP concentration was measured by UV-Vis spectroscopy using molar extinction coefficients at the wavelength of maximum absorption, as reported previously.⁴³

The nanoprobe was prepared by a rapid and facile method.²⁸ Ten μL of 1 wt% tween20 and 20 μL of 10 μM Gal-PEG₂₀₀₀-SH were added into 1 mL of 2 nM AuNP solution to obtain final concentrations of 0.01% Tween20 and 200 nM Gal-PEG₂₀₀₀-SH, respectively. After mixing, 6 μL of 100 μM thiolated DNA was added to the mixture and then, 2 M NaCl solution was added to obtain a final concentration of 0.8 M. After aging for 60 min at room temperature, unbound reagents were removed by centrifugation (12 000 rpm, 20 min, 4 °C). The precipitate was centrifuged and washed three times with PBS. The mPEG₂₀₀₀-

SH and DNA-modified AuNPs were prepared using a similar method.

Quantitation of DNA chains loaded on the AuNPs

DNA chains loaded on AuNPs were quantitated according to a published protocol.³⁰ Briefly, mercaptoethanol was added (final concentration 20 mM) into 1 nM nanoprobe solution; the mixture was incubated with stirring for 12 h at room temperature. The released DNA chains were collected *via* centrifugation, and the fluorescence intensity of FAM-DNA was measured with a fluorescence spectrometer. The fluorescence was converted to molar concentration of DNA chains *via* calculations from a standard linear calibration curve prepared with known concentrations of FAM-DNA with identical buffer pH, ionic strength and DNA concentrations.

Fluorescence measurements

In the fluorescence assay, [•]OH was generated through the Fenton reaction ($\text{Fe}^{2+} + \text{H}_2\text{O}_2 = \text{Fe}^{3+} + \text{OH}^- + \text{OH}^\bullet$) by different amounts of Fe²⁺ and excess H₂O₂ (1 : 6 mol per mol). Therefore, in the following experiments, the concentration of Fe²⁺ in the Fenton reaction served as the concentration of [•]OH. A certain concentration of [•]OH (Fe²⁺ with concentrations of 0, 0.01, 0.1, 0.2, 0.4, 0.6, 0.8, and 1 μM) generated through the Fenton reaction by different amounts of Fe²⁺ and H₂O₂ was added to 1 nM nanoprobe solution. After incubation at 37 °C for 15 min, the fluorescence intensity of the mixture was excited at 488 nm and measured at 520 nm. To investigate the specificity of the nanoprobe for [•]OH, 0.1% DMSO was added to the 1 nM nanoprobe solution before the addition of 1 μM Fe²⁺ and 6 μM H₂O₂. After incubation at 37 °C for 15 min, the fluorescence intensity of the mixture was excited at 488 nm and measured at 520 nm.

Kinetics of the nanoprobe

Fenton reagents were added to 1 nM nanoprobe solution. The fluorescence intensity of the mixture was scanned from 0 to 30 min in the absence and presence of 1 μM [•]OH (1 μM Fe²⁺ and 6 μM H₂O₂). The fluorescence intensity of the mixture was excited at 488 nm and measured at 520 nm.

Selectivity experiment

Fluorescence responses of 1 nM nanoprobe in PBS buffer (0.01 M, pH = 7.4) toward different ROS and RNS including [•]OH (1 μM), singlet oxygen (¹O₂, 1 μM), H₂O₂ (1 μM), superoxide anion radical (O₂^{•-}, 1 μM), *tert*-butyl hydroperoxide (TBHP, 1 μM), *tert*-butyl peroxy radical (OtBu[•], 1 μM), peroxyxynitrite anion (ONOO⁻, 1 μM), hypochlorite anion (ClO⁻, 1 μM) and Fe²⁺ (1 mM) were tested. The fluorescence intensity of mixture was detected after incubation at 37 °C for 15 min. ¹O₂ was formed by the addition of NaClO to H₂O₂ (1 : 1 mol per mol), and O₂^{•-} was obtained by 1 μM KO₂ in DMSO. OtBu[•] was obtained *via* the addition of TBHP to H₂O₂ (1 : 1 mol per mol). ONOO⁻ was obtained by the addition of NaNO₂ to H₂O₂ (1 : 1 mol per mol).^{31,44}



Stability of the nanoprobe

An equal volume of PBS or DMEM with 10% FBS was added into the nanoprobe (1 nM) and then, the fluorescence intensity of the nanoprobe was measured by a fluorescence spectrometer at 0, 1, 2, 3, 4, 5, 6 and 7 days.

Cell culture

Human normal liver cell line (L-02) was obtained from KeyGEN Biotech Co. Ltd. (Nanjing, China). L-02 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal calf serum (FBS, sigma), penicillin (100 $\mu\text{g mL}^{-1}$), and streptomycin (100 $\mu\text{g mL}^{-1}$) at 37 °C in a humidified incubator containing 5% CO₂ and 95% air. The medium was replenished every other day, and the cells were subcultured after reaching confluence.

MTT assay

The cytotoxicities of the nanoprobe and AuNPs to L-02 cells were investigated by using the MTT assay. Briefly, the L-02 cells were seeded into 96-well plates (4×10^3 cells per well) in a total volume of 200 μL per well and then incubated overnight. After the original medium was removed, AuNPs and the nanoprobe (0, 0.5, 1, 1.5, 2 or 2.5 nM) were added. The cells were incubated for 24 h. Then, 20 μL of MTT solution (5 mg mL^{-1} in PBS) was added for another 4 h. After that, the MTT solution was carefully removed. Formazan crystals were solubilized by the addition of 150 μL DMSO, and the absorbance at 490 nm was measured on an automated microtiter plate reader. Cell viability was calculated based on the absorbance at 490 nm.

Cellular uptake of the nanoprobe

L-02 cells were seeded onto 6-well plates and incubated with 1 nM AuNP and nanoprobe for 2 h. Cells with internalized nanoparticles were washed with PBS, trypsinized, and centrifuged to remove excess nanoparticles. Next, the cells were fixed with 1 mL fresh 2.5% glutaraldehyde. After one day, the cells were washed with PBS to remove the fixatives and then, they were dehydrated in an alcohol series, embedded in epon, and sliced to a ~ 75 nm thickness. TEM images of the slices were obtained with Hitachi HT7700.

ROS detection

In the experiments for ROS levels of APAP-induced liver injury, L-02 cells (4×10^3 cells per well) were seeded in 96-well blank plate and exposed to APAP (1–8 mM) for 4 h. After that, the cells were incubated with DCFH-DA (10 μM) for 30 min at 37 °C in the dark and then, they were washed in 100 μL ice-cold PBS. Fluorescence was measured using a microplate reader (Thermo Scientific Vario Skan Flash, USA) with the excitation wavelength at 488 nm and the emission wavelength at 520 nm.

In the experiment for the remediation effect of NAC or QUE, L-02 cells (4×10^3 cells per well) were seeded in a 96-well blank plate and exposed to 8 mM APAP for 4 h following incubation with NAC (0.5, 1, 2 mM) or QUE (5, 10, 20 μM) for 1 h and then, 8 mM APAP was added for another 4 h. After that, the

fluorescence was measured with the same experimental procedures as mentioned.

In the experiment for ROS levels of TP-induced liver injury, L-02 cells (4×10^3 cells per well) were seeded in a 96-well blank plate and exposed to TP (30, 60, 90, 120 nM) for 12 h. Another group was incubated for 3, 6, 12 and 24 h after TP (120 nM) was added. After that, the fluorescence was measured with the same experimental procedures as mentioned.

Confocal fluorescence imaging of $\cdot\text{OH}$ in living cells

L-02 cells were seeded into 35 mm confocal dishes (Glass Bottom Dish) at a density of 1×10^4 per dish and incubated for 24 h at 37 °C. The medium was then replaced with fresh serum-free culture medium containing APAP (8 mM) for 4 h and then incubated with 1 nM nanoprobe for different times at 37 °C. After that, the cells were washed three times with PBS. Confocal fluorescence imaging was performed to visualize the intracellular FAM fluorescence. FAM was excited at 488 nm with an argon ion laser, and the emission was collected from 505 to 535 nm.

For APAP-induced cell injury imaging, cells were treated with APAP (1–8 mM) for 4 h and then incubated with 1 nM nanoprobe for 2 h before imaging. For the remediation investigation, cells were pretreated with NAC (0.5, 1, 2 mM) or QUE (5, 10, 20 μM) for 1 h before APAP (8 mM) administration and then incubated with 1 nM nanoprobe for 2 h. After incubation, the cells were washed, and confocal fluorescence imaging was performed to visualize the intracellular FAM fluorescence.

For TP-induced cell injury imaging, cells were treated with TP (30, 60, 90, 120 nM) for 12 h and then incubated with 1 nM nanoprobe for 2 h before imaging. For another group, cells were treated with TP (120 nM) for 3, 6, 9, 12 and 24 h and then incubated with 1 nM nanoprobe for 2 h before imaging. After incubation, the cells were washed, and confocal fluorescence imaging was performed to visualize the intracellular FAM fluorescence.

Statistical analysis

Data were expressed as mean \pm SD from at least three experiments. One-way ANOVA was used to compare the treatment effects. $P < 0.05$ was considered to be statistically significant.

Conclusions

In summary, we have reported an $\cdot\text{OH}$ -responsive and hepatocyte-targeted nanoprobe, which exhibits several advantages including high sensitivity, selectivity, stability and good biocompatibility. The nanoprobe with Gal modification can be effectively internalized into liver cells *via* an ASGPR-mediated endocytosis pathway. Confocal fluorescence imaging results confirm that the nanoprobe can be successfully utilized for visualizing intracellular $\cdot\text{OH}$ during the process of drug-induced liver cell injury. The positive time using the nanoprobe is superior to those of ALT- and AST-based conventional methods. Although the emission wavelength of the nanoprobe is located in the visible region, which limits the *in vivo* application of DILI imaging, this study should significantly broaden the perspectives for the further development of



bioluminescent or near-infrared nanoprobes to predict DILI and to help prevent drug-induced side effects.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

This research was supported by the National Natural Science Foundation of China (21775166, 21505161), the Fundamental Research Funds for the Central Universities (2632017ZD10), the Natural Science Foundation of Jiangsu Province (BK20150701) and the Six Talent Peaks Project in Jiangsu Province.

References

- 1 S. Tujios and R. J. Fontana, *Nat. Rev. Gastroenterol. Hepatol.*, 2011, **8**, 202–211.
- 2 M. Chen, A. Suzuki, J. Borlak, R. J. Andrade and M. I. Lucena, *J. Hepatol.*, 2015, **63**, 503–514.
- 3 P. H. Hayashi, D. C. Rockey, R. J. Fontana, H. L. Tillmann, N. Kaplowitz, H. X. Barnhart, J. Gu, N. P. Chalasani, K. R. Reddy, A. H. Sherker, J. H. Hoofnagle and I. Drug-Induced Liver Injury Network, *Hepatology*, 2017, **66**, 1275–1285.
- 4 A. Srivastava, J. L. Maggs, D. J. Antoine, D. P. Williams, D. A. Smith and B. K. Park, *Handb. Exp. Pharmacol.*, 2010, **7**, 165–194.
- 5 J. S. Walsh and G. T. Miwa, *Annu. Rev. Pharmacol. Toxicol.*, 2011, **51**, 145–167.
- 6 M. Chen, V. Vijay, Q. Shi, Z. Liu, H. Fang and W. Tong, *Drug Discovery Today*, 2011, **16**, 697–703.
- 7 A. Nasr, T. J. Lauterio and M. W. Davis, *Adv. Ther.*, 2011, **28**, 842–856.
- 8 W. R. Proctor, A. J. Foster, J. Vogt, C. Summers, B. Middleton, M. A. Pilling, D. Shienson, M. Kijanska, S. Strobel, J. M. Kelm, P. Morgan, S. Messner and D. Williams, *Arch. Toxicol.*, 2017, **91**, 2849–2863.
- 9 E. S. Björnsson, O. M. Bergmann, H. K. Björnsson, R. B. Kvaran and S. Olafsson, *Gastroenterology*, 2013, **144**, 1419–1425.
- 10 R. P. van Swelm, C. Kramers, R. Masereeuw and F. G. Russel, *Crit. Rev. Toxicol.*, 2014, **44**, 823–841.
- 11 R. A. Nathwani, S. Pais, T. B. Reynolds and N. Kaplowitz, *Hepatology*, 2005, **41**, 380–382.
- 12 M. J. Czaja, *Semin. Liver Dis.*, 2007, **27**, 378–389.
- 13 D. J. Antoine, D. P. Williams and B. K. Park, *Expert Opin. Drug Metab. Toxicol.*, 2008, **4**, 1415–1427.
- 14 S. Russmann, G. A. Kullak-Ublick and I. Grattagliano, *Curr. Med. Chem.*, 2009, **16**, 3041–3053.
- 15 D. Pessayre, A. Mansouri, A. Berson and B. Fromenty, *Handb. Exp. Pharmacol.*, 2010, **11**, 311–365.
- 16 A. J. Shuhendler, K. Pu, L. Cui, J. P. Uetrecht and J. Rao, *Nat. Biotechnol.*, 2014, **32**, 373–380.
- 17 H. E. Moser and P. B. Dervan, *Science*, 1987, **238**, 645–650.
- 18 Y. Tang, F. Feng, F. He, S. Wang, Y. Li and D. Zhu, *J. Am. Chem. Soc.*, 2006, **128**, 14972–14976.
- 19 Q. Shen, Z. Nie, M. Guo, C. J. Zhong, B. Lin, W. Li and S. Yao, *Chem. Commun.*, 2009, 929–931.
- 20 C. Liu, W. Chen, Z. Qing, J. Zheng, Y. Xiao, S. Yang, L. Wang, Y. Li and R. Yang, *Anal. Chem.*, 2016, **88**, 3998–4003.
- 21 B. Tang, N. Zhang, Z. Chen, K. Xu, L. Zhuo, L. An and G. Yang, *Chemistry*, 2008, **14**, 522–528.
- 22 C. P. Liang, P. Q. Ma, H. Liu, X. Guo, B. C. Yin and B. C. Ye, *Angew. Chem., Int. Ed.*, 2017, **56**, 9077–9081.
- 23 Y. Sun, Q. Wang, J. Chen, L. Liu, L. Ding, M. Shen, J. Li, B. Han and Y. Duan, *Theranostics*, 2017, **7**, 4424–4444.
- 24 X. Wu, Y. J. Tan, H. T. Toh, L. H. Nguyen, S. H. Kho, S. Y. Chew, H. S. Yoon and X. W. Liu, *Chem. Sci.*, 2017, **8**, 3980–3988.
- 25 A. A. D'Souza and P. V. Devarajan, *J. Controlled Release*, 2015, **203**, 126–139.
- 26 N. Soh, K. Makihara, E. Sakoda and T. Imato, *Chem. Commun.*, 2004, 496–497.
- 27 C. A. Mirkin, R. L. Letsinger, R. C. Mucic and J. J. Storhoff, *Nature*, 1996, **382**, 607–609.
- 28 J. Li, B. Zhu, X. Yao, Y. Zhang, Z. Zhu, S. Tu, S. Jia, R. Liu, H. Kang and C. J. Yang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 16800–16807.
- 29 B. White, S. Banerjee, S. O'Brien, N. J. Turro and I. P. Herman, *J. Phys. Chem. C*, 2007, **111**, 13684–13690.
- 30 W. Pan, T. Zhang, H. Yang, W. Diao, N. Li and B. Tang, *Anal. Chem.*, 2013, **85**, 10581–10588.
- 31 M. Zhuang, C. Ding, A. Zhu and Y. Tian, *Anal. Chem.*, 2014, **86**, 1829–1836.
- 32 J. He, X. Yang, B. Men and D. Wang, *J. Environ. Sci.*, 2016, **39**, 97–109.
- 33 W. Zhou, Y. Cao, D. Sui and C. Lu, *Angew. Chem., Int. Ed.*, 2016, **55**, 4236–4241.
- 34 A. Bertolini, A. Ferrari, A. Ottani, S. Guerzoni, R. Tacchi and S. Leone, *CNS Drug Rev.*, 2006, **12**, 250–275.
- 35 K. Du, A. Ramachandran and H. Jaeschke, *Redox Biol.*, 2016, **10**, 148–156.
- 36 J. A. Hinson, D. W. Roberts and L. P. James, *Handb. Exp. Pharmacol.*, 2010, **196**, 369–405.
- 37 C. C. Huang, W. Y. Pan, M. T. Tseng, K. J. Lin, Y. P. Yang, H. W. Tsai, S. M. Hwang, Y. Chang, H. J. Wei and H. W. Sung, *Biomaterials*, 2016, **74**, 53–63.
- 38 R. Zhang, J. Zhao, G. Han, Z. Liu, C. Liu, C. Zhang, B. Liu, C. Jiang, R. Liu, T. Zhao, M. Y. Han and Z. Zhang, *J. Am. Chem. Soc.*, 2016, **138**, 3769–3778.
- 39 A. W. Boots, G. R. Haenen and A. Bast, *Eur. J. Pharmacol.*, 2008, **585**, 325–337.
- 40 P. E. Lipsky and X. L. Tao, *Semin. Arthritis Rheum.*, 1997, **26**, 713–723.
- 41 X. J. Li, Z. Z. Jiang and L. Y. Zhang, *J. Ethnopharmacol.*, 2014, **155**, 67–79.
- 42 Y. Ma, Z. Wang, M. Zhang, Z. Han, D. Chen, Q. Zhu, W. Gao, Z. Qian and Y. Gu, *Angew. Chem., Int. Ed.*, 2016, **55**, 3304–3308.
- 43 S. Wang, W. Lu, O. Tovmachenko, U. S. Rai, H. Yu and P. C. Ray, *Chem. Phys. Lett.*, 2008, **463**, 145–149.
- 44 F. Liu, T. Bing, D. Shangguan, M. Zhao and N. Shao, *Anal. Chem.*, 2016, **88**, 10631–10638.

